---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-041100"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:37:28.901723+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunocore reports positive Phase 1 data for brenetafusp in ovarian cancer at ESMO 2024

## Summary
- Phase 1 monotherapy: 58% disease control, 6.5% RECIST response rate, median PFS 3.3 months in heavily pre-treated platinum-resistant ovarian cancer.
- Phase 1 combo with chemo: 23% RECIST response rate, 69% disease control, 82% ctDNA molecular response rate.
- T cell fitness signature associated with OS (28 vs 11 months) and PFS (5 vs 2 months) for KIMMTRAK in uveal melanoma, across ImmTAC platform.
- Brenetafusp well tolerated; no treatment-related discontinuations; cytokine release syndrome manageable (57% Grade 1).

## SEC filing metadata
- accession: 0001140361-24-041100
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036124041100/0001140361-24-041100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036124041100/ef20035872_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-041100
- JSON: https://secwatch.observer/filing/0001140361-24-041100.json
- Plain text: https://secwatch.observer/filing/0001140361-24-041100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.